ICCMIcecure Medical Ltd

IceCure's ProSense Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked IceCure's ProSense Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO...

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement PR Newswire...

IceCure Medical (ICCM) delivered earnings and revenue surprises of -100.00% and -54.90%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IceCure Reports First Quarter 2026 Financial Results: ProSense Sales Increase Substantially in the U.S. and North America IceCure Reports First Quarter 2026 Financial Results: ProSense Sales Increase Substantially in the U.S. and North America PR Newswire CAESAREA, Israel, May 12, 2026 Pent-up...

The Oncology Institute (TOI) delivered earnings and revenue surprises of +71.43% and +1.54%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IceCure Showcases ProSense Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market IceCure Showcases ProSense Cryoablation at...

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025 IceCure Participates in Society...

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private...

(RTTNews) - IceCure Medical Ltd. (ICCM) on Wednesday, has reported favorable top-line results from its ICESECRET clinical trial, which assessed the ProSense Cryoablation System for the treatment of...